24. Poteligeo

fda
Sold in Japan since 2012, Poteligeo is the first anti-CCR4 antibody to be made available in the U.S. (FDA)

Active ingredient: mogamulizumab-kpkc
Diseases: Mycosis fungoides and Sézary disease
Peak sales estimate: n/a
Approved: August 8
Company: Kyowa Hakko Kirin 

The scoop: Sold in Japan since 2012, Poteligeo is the first anti-CCR4 antibody to be made available in the U.S., according to the manufacturer Kyowa Hakko Kirin. It was approved in August for relapsed or resistant mycosis fungoides and Sézary syndrome—the two most common types of cutaneous T-cell lymphoma—after at least one previous therapy. Mycosis fungoides account for about half of all cases, while Sézary disease numbers around 3%, but is more aggressive. They are often mistaken for other common skin conditions.

Kyowa has filed an application in the European Union, but its also testing the drug in early-phase combination trials with its in-house IDO inhibitor, KHK2455, as well as with Bristol-Myers Squibb’s Opdivo and AstraZeneca’s Imfinzi against solid tumors. In 2017, Poteligeo brought in 1.9 billion yen, or about $17 million in sales. Kyowa’s approval came just a few months after its FDA nod this year for Crysvita (burosumab-twza), developed with Ultragenyx, for X-linked hypophosphatemia. — Conor Hale 

24. Poteligeo

Suggested Articles

Rachel Humphrey, M.D., who joined CytomX as chief medical officer after heading immuno-oncology at AstraZeneca and Eli Lilly, has made her exit.

Scientists have discovered a scorpion toxin could inspire treatments to block the inflammation that triggers chronic pain.

The phase 2 success keeps Hal Barron’s group on track to file for approval in multiple myeloma by the end of the year.